$4.39 0.1 2.6%
Last Trade - 3:16pm
| Market Cap | £41.7m |
| Enterprise Value | £33.1m |
| Revenue | £20.0m |
| Position in Universe | 5560th / 6841 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.61 | 3.22 | 5.07 | 3.25 | 5.53 | 27.5 | 41.2 | 46.5 | +114.1% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biocept, Inc. is a molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | June 28, 2013 |
| Public Since | February 5, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | 104 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 13,402,368 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 5810 Nancy Ridge Dr, SAN DIEGO, 92121-2834, United States |
| Web | https://biocept.com/ |
| Phone | +1 858 3208200 |
| Contact | () |
| Auditors | Mayer Hoffman & McCann P.C. |
As of 3:16pm, shares in Biocept Inc are trading at $4.39, giving the company a market capitalisation of £41.7m. This share price information is delayed by 15 minutes.
Shares in Biocept Inc are currently trading at $4.39 and the price has moved by 20.09% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biocept Inc price has moved by -19.68% over the past year.
Of the analysts with advisory recommendations for Biocept Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biocept Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Biocept Inc is scheduled to issue upcoming financial results on the following dates:
Biocept Inc does not currently pay a dividend.
Biocept Inc does not currently pay a dividend.
Biocept Inc does not currently pay a dividend.
To buy shares in Biocept Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biocept Inc are currently trading at $4.39, giving the company a market capitalisation of £41.7m.
Here are the trading details for Biocept Inc:
Based on an overall assessment of its quality, value and momentum, Biocept Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Biocept Inc are currently priced at $4.39. At that level they are trading at 0.367% discount to the analyst consensus target price of 0.00.
Analysts covering Biocept Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.57 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocept Inc. Over the past six months, the relative strength of its shares against the market has been -24.77%. At the current price of $4.39, shares in Biocept Inc are trading at -26.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biocept Inc.
Biocept Inc's management team is headed by:
Here are the top five shareholders of Biocept Inc based on the size of their shareholding:
